Ulenistamab (PBP1510) is a first-in-class hunamised IgG1 monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF). Ulenistamab can be used for pancreatic cancer (PC) research.
Ulenistamab (PBP1510) suppresses the proliferation of the PC cell lines (CFPAC-1 and BxPC-3). The migration and invasion of PC cell lines is significantly reduced[1].
Pharmacokinetic (PK) characteristics and immunogenicity of PBP1510 (up to 20 mg/kg), are examined in single dose studies in 6 monkeys. In monkey studies, a dose-proportional increase in systemic exposure was observed at low and high doses[1].
References:
[1]. Kedar Diwakar Mandakhalikar, et al. First-in-class monoclonal antibody (mAb) PBP1510 targeting pancreatic adenocarcinoma upregulated factor (PAUF) for pancreatic cancer (PC) treatment: Preclinical perspectives. Journal of Clinical Oncology 2022 40:16_suppl, e16274-e16274.